Cargando…
A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer
The standard treatment for prostate cancer (PCa) is androgen deprivation therapy (ADT) that blocks transcriptional activity of androgen receptor (AR). However, ADT invariably leads to the development of castration-resistant PCa (CRPC) with restored activity of AR. CRPC can be further treated with CY...
Autores principales: | Han, Dong, Gao, Shuai, Valencia, Kevin, Owiredu, Jude, Han, Wanting, de Waal, Eric, Macoska, Jill A, Cai, Changmeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351670/ https://www.ncbi.nlm.nih.gov/pubmed/28036278 http://dx.doi.org/10.18632/oncotarget.14296 |
Ejemplares similares
-
RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition
por: Han, Wanting, et al.
Publicado: (2022) -
TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells
por: Zhou, Feng, et al.
Publicado: (2019) -
Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer
por: Han, Wanting, et al.
Publicado: (2022) -
Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer
por: Gao, Shuai, et al.
Publicado: (2020) -
Androgen receptor variants: another twist in the plot
por: Macoska, Jill A.
Publicado: (2017)